Featured Speakers and Topics
Dr. Maria Willrich will discuss “Recent Studies of sFLC Assays and Their Impact on Clinical Assessment”
Dr. Angela Dispenzieri will discuss “The Importance of Testing for Monoclonal Proteins in Non-Tissue Diagnosis of Cardiac Amyloidosis”
Abstract
Serum free light chain (sFLC) tests have advanced the prediction, diagnosis, and monitoring of plasma cell disorders. This webinar features two leading experts who will compare the performance of sFLC assays in the contexts of Multiple Myeloma, including its precursors such as MGUS and smoldering myeloma, and Amyloidosis. With the introduction of updated guidelines for monoclonal gammopathies and a new, 2023 consensus for cardiac amyloidosis, attendees will gain valuable insights into the interchangeability of assay platforms and key considerations for optimizing testing triage. The discussion will also address reference intervals, method selection, and strategies to enhance assay specificity for improved testing accuracy.
Learning Objectives
- Describe the use of sFLC assays in diagnosing and managing plasma cell disorders.
- Discuss efforts to standardize sFLC assays across platforms and reference intervals with clinical implications.
- Identify the role of monoclonal proteins, especially sFLC, with regards to the 2023 American College of Cardiology Expert Consensus on Cardiac Amyloidosis.
Speakers
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.